# KYMR catalysts: Kymera Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/kymr/catalysts

> Kymera Therapeutics, Inc. (KYMR) has 7 upcoming catalysts. The next is the KT-621 trial start, mid-2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for KYMR?

Kymera Therapeutics, Inc. (KYMR) has 7 upcoming catalysts. The next is the KT-621 trial start, mid-2027. SEC Form 8-K: "The disclosure under this Item 8.01 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about the Company's expectations regarding strategy, business plans and objectives on the development of KT-621, including the therapeutic potential, clinical benefits and safety thereof, the initiation of Phase 3 trials of KT-621 in patients with AD by mid-2027, and anticipated Phase 2b topline data readout of KT-621 in patients with moderate to severe AD expected by year-end 2026." [Calendar and source filings](https://sec-api.dev/companies/kymr/catalysts)

Source: SEC Form 8-K, accession 0001193125-26-281817, https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/companies/kymr/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Kymera Therapeutics, Inc. |
| Ticker | KYMR (Nasdaq) |
| SEC CIK | 1815442 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/kymr |

## Cash runway

Cash $1.65B as of 2026-09-30; quarterly burn $77.9M; about 63.4 months of runway at that rate (XBRL company facts, accession 0001193125-26-436975).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2024 | [KT-621 trial start](https://sec-api.dev/pdufa/kt-621) | KYMR |  | completed | "In October 2024, Kymera initiated a Phase 1 clinical trial with KT-621 in healthy volunteers." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312525037588/d922874dex991.htm)) |
| 1H 2025 | [KT-621 topline data readout](https://sec-api.dev/pdufa/kt-621) | KYMR |  | scheduled | "The disclosure under this Item 8.01 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about the Company's expectations regarding strategy, business plans and objectives for clinical development of its clinical and preclinical pipeline including the therapeutic potential, clinical benefits and safety thereof, the Phase 1 data readout of KT-621 in the first half of 2025 and plans to initiate a Phase 1b trial in atopic dermatitis (AD) patients in the second quarter of" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233d8k.htm)) |
| February 27, 2025 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "(February 27, 2025)  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided business highlights and updates on its pipeline." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312525037588/d922874dex991.htm)) |
| Q2 2025 | [KT-621 trial start](https://sec-api.dev/pdufa/kt-621) | KYMR |  | scheduled | "Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233dex991.htm)) |
| Q2 2025 | [KT-295 trial start](https://sec-api.dev/pdufa/kt-295) | KYMR |  | scheduled | "File KT-295 IND and initiate dosing in the Phase 1 healthy volunteer clinical trial in the second quarter of 2025, with Phase 1 data expected in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233dex991.htm)) |
| May 9, 2025 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312525116443/d27625dex991.htm)) |
| August 11, 2025 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000095017025106227/kymr-ex99_1.htm)) |
| Nov 2025 | [KT-621 trial start](https://sec-api.dev/pdufa/kt-621) | KYMR |  | completed | "Dosing commenced in November 2025 for the KT-621 BROADEN2 Phase 2b trial, a global, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of three doses of KT-621 in approximately 200 patients with moderate to severe AD over 16 weeks." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526011104/d78447dex991.htm)) |
| November 4, 2025 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312525263540/kymr-ex99_1.htm)) |
| Jan 2026 | [KT-621 trial start](https://sec-api.dev/pdufa/kt-621) | KYMR |  | completed | "In January 2026, the Company commenced dosing in the BREADTH Phase 2b clinical trial, a global, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and tolerability of three doses of KT-621 in approximately 264 adult patients with moderate to severe eosinophilic asthma over 12 weeks." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/kymr-ex99_1.htm)) |
| Q1 2026 | [KT-621 trial start](https://sec-api.dev/pdufa/kt-621) | KYMR | asthma | scheduled | "our expectations regarding strategy, business plans and objectives on the development of KT-621, including the therapeutic potential, clinical benefits and safety thereof, the initiation of the Phase 2b study of KT-621 in patients with asthma in the first quarter of 2026, the effect of initial parallel development of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312525310670/d77337dex991.htm)) |
| Feb 2026 | [KT-579 trial start](https://sec-api.dev/pdufa/kt-579) | KYMR |  | completed | "In February 2026, after IND-clearance from the FDA, the Company commenced dosing in the first-in-human KT-579 Phase 1 clinical trial in healthy volunteers." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/kymr-ex99_1.htm)) |
| February 26, 2026 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526073386/kymr-ex99_1.htm)) |
| April 30, 2026 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/kymr-ex99_1.htm)) |
| August 5, 2026 | [Kymera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kymr/catalysts) | KYMR |  | completed | "Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/kymr-ex99_1.htm)) |
| late 2026 | [KT-621 topline data readout](https://sec-api.dev/pdufa/kt-621) | KYMR | moderate to severe AD | scheduled | "The Company plans to report topline data by year-end 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm)) |
| October 29, 2026 | [KT-579 earnings report](https://sec-api.dev/pdufa/kt-579) | KYMR |  | completed | "Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm)) |
| mid-2027 | [KT-621 trial start](https://sec-api.dev/pdufa/kt-621) | KYMR |  | scheduled | "The disclosure under this Item 8.01 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about the Company's expectations regarding strategy, business plans and objectives on the development of KT-621, including the therapeutic potential, clinical benefits and safety thereof, the initiation of Phase 3 trials of KT-621 in patients with AD by mid-2027, and anticipated Phase 2b topline data readout of KT-621 in patients with moderate to severe AD expected by year-end 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm)) |
| June 2027 | [KT-621 primary completion](https://sec-api.dev/pdufa/kt-621) | KYMR | Atopic Dermatitis | scheduled | "NCT07217015 (A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217015)) |
| Jun to Sep 2027 | [KT-621 topline data readout](https://sec-api.dev/pdufa/kt-621) | KYMR | Atopic Dermatitis | scheduled | "NCT07217015 (A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217015)) |
| December 2027 | [KT-621 primary completion](https://sec-api.dev/pdufa/kt-621) | KYMR | Eosinophilic Asthma | scheduled | "NCT07323654 (A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07323654)) |
| Dec 2027 to Mar 2028 | [KT-621 topline data readout](https://sec-api.dev/pdufa/kt-621) | KYMR | Eosinophilic Asthma | scheduled | "NCT07323654 (A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07323654)) |
| December 2028 | [KT-621 primary completion](https://sec-api.dev/pdufa/kt-621) | KYMR | Asthma (Diagnosis) | scheduled | "NCT07677059 (A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07677059)) |
| Dec 2028 to Mar 2029 | [KT-621 topline data readout](https://sec-api.dev/pdufa/kt-621) | KYMR | Asthma (Diagnosis) | scheduled | "NCT07677059 (A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Kymera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07677059)) |

## Drugs

- [KT-295](https://sec-api.dev/pdufa/kt-295): 
- [KT-579](https://sec-api.dev/pdufa/kt-579): 
- [KT-621](https://sec-api.dev/pdufa/kt-621): moderate to severe eosinophilic asthma, with topline data, moderate to severe ad, asthma, Eosinophilic Asthma, Atopic Dermatitis, Asthma (Diagnosis)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/kymr/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KYMR catalysts: Kymera Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/kymr/catalysts

```bibtex
@misc{secapidev_companies_kymr_catalysts_20261116,
  title        = {KYMR catalysts: Kymera Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/kymr/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_kymr_catalysts_20261116","title":"KYMR catalysts: Kymera Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/kymr/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
